Furue H, Uchino H, Orita K, Kimura T, Goto Y, Kondo T, Sato S, Takino T, Taguchi T, Nakao I
Gan To Kagaku Ryoho. 1985 Jun;12(6):1272-7.
We reported previously that Schizophyllan (SPG) combined with MMC + 5-FU (MF regimen) or Tegafur (F regimen) had a significant life-prolonging effect over chemotherapeutic regimens in patients with inoperable and recurrent gastric cancer in a randomized controlled study. In the present paper, we have further investigated the effect of SPG on life-span followed-up for more than 2 years. A significant life-prolonging effect of SPG was reconfirmed in patients given either the MF regimen (154 patients) or the F regimen (213 patients). Thus, SPG combined with chemotherapeutics has proved to be useful for treating patients with inoperable and recurrent gastric cancer, resulting in a significant prolongation of life-span without serious side effects despite having no influence on tumor size.
我们之前报道过，在一项随机对照研究中，裂褶多糖（SPG）联合丝裂霉素 + 5-氟尿嘧啶（MF方案）或替加氟（F方案）对无法手术及复发性胃癌患者的化疗方案具有显著的延长生存期作用。在本文中，我们进一步研究了SPG对随访超过2年的生存期的影响。在接受MF方案（154例患者）或F方案（213例患者）的患者中再次证实了SPG具有显著的延长生存期作用。因此，已证明SPG联合化疗药物可有效治疗无法手术及复发性胃癌患者，可显著延长生存期且无严重副作用，尽管对肿瘤大小没有影响。
